FIM
ENTA icon

Freedom Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Freedom Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,573
Closed -$217K – 707
2019
Q2 		$217K Sell
2,573
-3,186
-55% -$287K 0.02% 615
2019
Q1 		$550K Buy
5,759
+1,197
+26% +$107K 0.04% 359
2018
Q4 		$323K Buy
4,562
+533
+13% +$40.9K 0.03% 552
2018
Q3 		$366K Sell
4,029
-441
-10% -$44.2K 0.02% 644
2018
Q2 		$518K Sell
4,470
-27,157
-86% -$2.71M 0.03% 536
2018
Q1 		$2.56M Buy
31,627
+528
+2% +$40.6K 0.13% 124
2017
Q4 		$1.82M Buy
31,099
+997
+3% +$49.9K 0.09% 176
2017
Q3 		$1.41M Sell
30,102
-1,463
-5% -$58.8K 0.08% 221
2017
Q2 		$1.14M Buy
31,565
+173
+0.6% +$5.53K 0.06% 270
2017
Q1 		$967K Sell
31,392
-3,934
-11% -$123K 0.06% 302
2016
Q4 		$1.18M Sell
35,326
-9,545
-21% -$274K 0.07% 205
2016
Q3 		$1.19M Sell
44,871
-1,144
-2% -$26.6K 0.08% 194
2016
Q2 		$1.01M Sell
46,015
-5,510
-11% -$144K 0.07% 216
2016
Q1 		$1.51M Buy
51,525
+6,689
+15% +$186K 0.11% 122
2015
Q4 		$1.48M Buy
44,836
+35,534
+382% +$1.16M 0.11% 132
2015
Q3 		$799K Sell
9,302
-11,612
-56% -$499K 0.08% 205
2015
Q2 		$941K Buy
+20,914
New +$814K 0.1% 168

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Freedom Investment Management's ENTA Position: Q3 2019 in Review

Freedom Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q3 2019, closing a stake of 2,573 shares — an estimated $217K sold.

Freedom Investment Management first reported a position in ENTA in Q2 2015 and held it in 17 quarters. The position peaked at $2.56M in Q1 2018. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

  • Freedom Investment Management reported no remaining Enanta Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Freedom Investment Management sold 2,573 Enanta Pharmaceuticals shares in Q3 2019, an estimated $217K.
  • Freedom Investment Management first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 17 quarters.
  • Freedom Investment Management's Enanta Pharmaceuticals position peaked at $2.56M in Q1 2018.
  • 176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Freedom Investment Management's 13F filing for Q3 2019, filed 5 Nov 2019.